Neuroscience Is The Next Oncology: Why Biogen Is Doubling Down

 
• By Eleanor Malone

While other large biopharma companies are withdrawing from CNS research, Biogen is rare in not only staying in, but doubling down. Executives at the company’s 40th anniversary event in Switzerland explained why.

Unrecognizable male scientist is plugging a microscopy app into a brain study interface. Science concept for biosciences, molecular engineering, bioengineering, pharmacogenomics, pharmacogenetics.
Biogen sees rapid progress in many aspects of CNS R&D • Source: Shutterstock

More from Leadership

More from Scrip